167 related articles for article (PubMed ID: 34089352)
1. Feasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability.
Chen L; Chen CS; Sun Y; Henry NL; Stringer KA; Hertz DL
Cancer Chemother Pharmacol; 2021 Sep; 88(3):475-483. PubMed ID: 34089352
[TBL] [Abstract][Full Text] [Related]
2. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.
Sun Y; Kim JH; Vangipuram K; Hayes DF; Smith EML; Yeomans L; Henry NL; Stringer KA; Hertz DL
Breast Cancer Res Treat; 2018 Oct; 171(3):657-666. PubMed ID: 29946863
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
[TBL] [Abstract][Full Text] [Related]
4. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
Kraff S; Lindauer A; Joerger M; Salamone SJ; Jaehde U
Ther Drug Monit; 2015 Dec; 37(6):725-32. PubMed ID: 25774704
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and biochemical analysis in the treatment of weekly paclitaxel in relapsed breast cancer.
Kim R; Osaki A; Toge T
Oncol Rep; 2001; 8(5):1171-6. PubMed ID: 11496337
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
[TBL] [Abstract][Full Text] [Related]
7. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.
Crombag MBS; de Vries Schultink AHM; Koolen SLW; Wijngaard S; Joerger M; Schellens JHM; Dorlo TPC; van Erp NP; Mathijssen RHJ; Beijnen JH; Huitema ADR
Pharm Res; 2019 Jan; 36(2):33. PubMed ID: 30617624
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy.
Kraff S; Nieuweboer AJ; Mathijssen RH; Baty F; de Graan AJ; van Schaik RH; Jaehde U; Joerger M
Cancer Chemother Pharmacol; 2015 May; 75(5):975-83. PubMed ID: 25761456
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
[TBL] [Abstract][Full Text] [Related]
10. Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer.
Gota V; Nookala M; Bonda A; Karanam A; Shriyan B; Kembhavi Y; Gurjar M; Patil A; Singh A; Goyal N; Gupta S
Cancer Med; 2021 May; 10(9):3068-3076. PubMed ID: 33826243
[TBL] [Abstract][Full Text] [Related]
11. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
[TBL] [Abstract][Full Text] [Related]
13. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
Kim R; Osaki A; Toge T
Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
Danesi R; Conte PF; Del Tacca M
Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
[TBL] [Abstract][Full Text] [Related]
17. Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study.
Borgå O; Henriksson R; Bjermo H; Lilienberg E; Heldring N; Loman N
Adv Ther; 2019 May; 36(5):1150-1163. PubMed ID: 30879251
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
Seidman AD; Hudis CA; Albanell J; Tong W; Tepler I; Currie V; Moynahan ME; Theodoulou M; Gollub M; Baselga J; Norton L
J Clin Oncol; 1998 Oct; 16(10):3353-61. PubMed ID: 9779712
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
